• Record quarterly revenue of $14.1 million, a 210% increase on Q1 FY25 and a 47% increase on Q4 FY25
• Substantial investment in cannabis flower procurement and working capital to meet European demand
• Completed dual listing on Frankfurt Stock Exchange

Australian life sciences, pharmaceutical and consumer health products Company, Bioxyne Limited (ASX:BXN) ('Bioxyne' 'Group' or the 'Company') is pleased to report strong Q1 FY26 trading performance with revenue up 47% on the prior quarter and 210% on the prior year corresponding period. To meet the significant demand from Europe the Company made a material investment in cannabis flower during the quarter with inventory on hand at ~A$6.1m (up from $3.6m in Q4 FY25). As a consequence, and together with an increase in other net working capital of A$1.5m the Company returned an operating cash outflow of $4.1m in the quarter, with cash receipts of A$12.9m. Additional capex during the quarter was $0.25m. Trade receivables increased from $2.4m in Q4 FY25 to $6.0m in Q1 FY26, deferring cash receipts, because of extending payment terms to key clients that are increasing order volumes. Total inventory increased from $3.6m to $6.1m from Q4 FY25 to Q1 FY26 as the business prepares to scale up its white label offering and cannabis flower revenues. The Group's results were driven by Breathe Life Sciences (BLS) Australia, Australia's leading manufacturer and wholesaler of novel medicines, including cannabis, MDMA, and Psilocybin. Europe made a significant contribution with the first shipment to Adrex Pharma in Germany. The Company successfully listed on the Frankfurt Stock Exchange (FSE) on 13 October 2025 trading under the ticker code PR8.F.

The Company is forecasting FY26 revenue of $65m - $75m and FY26 EBITDA of $11.5m - $13.5m.

The Company is focused on improving processes, including ERP systems, to manage the growing business in Australia, UK and EU, planning and execution of manufacturing/distribution facilities in UK and Europe to meet growing demand, gaining EU GMP certification in Czechia for distribution to European markets, and scaling its medicinal cannabis product sales in the UK and European markets with local partners.